Combining a histone deacetylase inhibitor drug with immunotherapy agents has been deemed safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial.
Combining a histone deacetylase inhibitor drug with immunotherapy agents has been deemed safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial.